findmyKOL
Clinical trialNCT01904604CompletedPhase 2Interventional

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment75Food HypersensitivityHypersensitivityHypersensitivity, ImmediatePeanut Hypersensitivity
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Food allergy occurs when the immune system reacts against foods. The immune system is the part of the body that protects us from illness and germs, but it can also cause allergies. Peanut allergy occurs in 1 - 2% of people in the United States and other Western countries. There is proof that allergy to peanut is increasing. Allergic reactions to peanut can be severe and life threatening. The only way that you can prevent an allergic reaction is to avoid exposure to peanuts. However, peanut proteins are found in a variety of foods and people can be accidently exposed to peanut proteins. Treatment for accidental exposure include antihistamines (medications like Benadryl), and injectable epinephrine (adrenalin) which must be carried at all times. DBV Technologies has developed an epicutaneous delivery system, a patch that puts the peanut protein on the skin.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Arkansas Children'S Hospital

    Little Rock, Arkansas, United States

  • National Jewish Health

    Denver, Colorado, United States

  • the Johns Hopkins University

    Baltimore, Maryland, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, United States

  • University of North Carolina at Chapel Hill School of Medicine

    Chapel Hill, North Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

High-dose DBV712 Viaskin® PatchLow-dose DBV712 Viaskin® PatchPlacebo Viaskin® Patch
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Sept 2013
Primary completion
31 Aug 2015
Completion
21 Aug 2018
Last update posted
1 Jul 2019
Registered enrollment
75
Registry id
NCT01904604

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.